The journey to understanding incretin systems: Theory, practice and more theory

Daisuke Yabe; Hitoshi Kuwata; Yutaka Seino

doi:10.1111/jdi.13123

The journey to understanding incretin systems: Theory, practice and more theory

J Diabetes Investig. 2019 Sep;10(5):1171-1173. doi: 10.1111/jdi.13123. Epub 2019 Aug 20.

Authors

Daisuke Yabe^{1

2

3}, Hitoshi Kuwata^{2

4

5}, Yutaka Seino^{2

4}

Affiliations

¹ Department of Diabetes and Endocrinology, Gifu University Graduate School of Medicine, Gifu, Japan.
² Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Japan.
³ Division of Molecular and Metabolic Medicine, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, Kobe, Japan.
⁴ Center for Diabetes, Metabolism and Endocrinology, Kansai Electric Power Medical Research Institute, Osaka, Japan.
⁵ Center for Clinical Nutrition and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.

Abstract

Accumulating clinical data on incretin-based dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in the past decade have clearly confirmed their safety and efficacy as antidiabetes drugs. However, the journey to understand the incretin system and its role in health and disease continues.

MeSH terms

Diabetes Mellitus, Type 2 / drug therapy*
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
Glucagon-Like Peptide-1 Receptor / agonists*
Humans
Hypoglycemic Agents / therapeutic use*
Incretins / therapeutic use*
Prognosis

Substances

Dipeptidyl-Peptidase IV Inhibitors
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Incretins